The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma
Open Access
- 31 August 2004
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 165 (2) , 511-521
- https://doi.org/10.1016/s0002-9440(10)63316-0
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR)Human Molecular Genetics, 2003
- Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane RegionMolecular and Cellular Biology, 2003
- RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid TumorsJournal of Clinical Endocrinology & Metabolism, 2002
- Novel germline RET mutation segregating with papillary thyroid carcinomasGenes, Chromosomes and Cancer, 2001
- C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RETOncogene, 2001
- Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling CascadeMolecular and Cellular Biology, 2001
- Differential Effects of Leukocyte Common Antigen-related Protein on Biochemical and Biological Activities of RET-MEN2A and RET-MEN2B Mutant ProteinsPublished by Elsevier ,2001
- Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-METOncogene, 1999
- Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domainOncogene, 1997
- Histogenesis of medullary carcinoma of the thyroidJournal of Clinical Pathology, 1966